ALS Blood Test Predicts Symptoms Years Early

A significant advancement in ALS research has been made with the identification of specific blood protein changes that occur months, or even years, before symptoms of the neurodegenerative disease manifest. This discovery, reported by researchers analyzing data from the National Institutes of Health-funded Pre-fALS study, holds promise for early intervention.

The study involved analyzing plasma samples from 137 participants, 33 of whom later developed ALS or frontotemporal dementia. Using advanced proteomic analysis, scientists identified 92 proteins with altered levels preceding symptom onset. Machine-learning models pinpointed a crucial panel of 19 proteins, including neurofilament light chain (NfL), that accurately predict disease onset.

These biomarkers enable an estimation of symptom onset with an average error of approximately 18 months, offering a critical window for potential early treatment. This predictive capability is particularly valuable as researchers explore therapies aimed at delaying or preventing the disease before it becomes clinically apparent, potentially before irreversible nerve damage occurs.

The findings were further validated using data from the UK Biobank, suggesting broader relevance beyond inherited forms of ALS. With the advent of preventative gene-targeting treatments, reliable biofluid-based signatures like these are crucial for identifying individuals at risk and initiating timely interventions, marking a pivotal moment for ALS treatment development.